
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Pharmacological Strategies for the Management of Severe Alcohol-associated Hepatitis: A Systematic Review and Meta-analysis</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Pharmacological Strategies for the Management of Severe Alcohol-associated Hepatitis: A Systematic Review and Meta-analysis</strong></summary>
            <div>
                <ul><li>Authors: Alvi H. Islam, Claudia Alvizuri, et al.</li><li>Journal: Clinical Gastroenterology and Hepatology</li><li>Publication Date: May 4, 2025</li><li>This is a systematic review and meta-analysis of RCTs examining pharmacological treatments for severe AH.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What is the reported short-term mortality rate (within three months) for severe alcohol-associated hepatitis (AH)?</li><li>2. According to the guidelines, what MDF score is typically used as a cutoff for considering corticosteroid treatment in AH?</li><li>3. Which pharmacological agent, when combined with corticosteroids, showed a statistically significant reduction in 28-day mortality compared to corticosteroids alone?</li><li>4. What is the primary mechanism of liver injury in AH?</li><li>5. Name one therapy that showed a 90-day mortality benefit compared to corticosteroids.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Background</strong></summary>
            <div>
                <ul><li>AH is a severe form of ALD.</li><li>Short-term mortality can reach 50% within 3 months.</li><li>Optimal pharmacological treatment for severe AH is uncertain.</li></ul>
                
        <details>
            <summary><strong>ALD Burden</strong></summary>
            <div>
                <ul><li>ALD is a leading cause of liver-related mortality worldwide.</li><li>It&#x27;s a common indication for liver transplantation.</li><li>ALD accounts for 41.7% of cirrhosis-related deaths.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>AH Characteristics</strong></summary>
            <div>
                <ul><li>AH involves sudden jaundice onset.</li><li>Progressive inflammatory liver injury occurs.</li><li>Risk of multiorgan failure ↑.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Need for Effective Therapies</strong></summary>
            <div>
                <ul><li>Current AH treatment options often fail to alter long-term prognosis.</li><li>There&#x27;s an urgent need for more effective therapies.</li><li>AH is associated w/ serious adverse events: acute kidney injury, hepatorenal syndrome, infections.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Mechanisms of Liver Injury in AH</strong></summary>
            <div>
                <ul><li>Severe inflammatory response is central.</li><li>Direct hepatocyte injury occurs via oxidative stress.</li><li>Indirect ethanol-induced liver damage happens via microbial dysbiosis &amp; loss of intestinal barrier integrity.</li></ul>
                
        <details>
            <summary><strong>Consequences</strong></summary>
            <div>
                <ul><li>Impaired hepatocyte regeneration.</li><li>Liver synthetic dysfunction.</li><li>Ultimately, liver failure.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Pharmacotherapies</strong></summary>
            <div>
                <ul><li>Target mechanisms of alcohol-induced liver injury.</li><li>Include anti-inflammatory drugs (corticosteroids), pro-regeneration drugs (G-CSF), therapies targeting gut-liver axis.</li><li>No significant improvement in mortality &amp; morbidity outcomes despite advancements.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Current Treatment Recommendations</strong></summary>
            <div>
                <ul><li>Achieving &amp; maintaining alcohol abstinence + supportive care (nutritional support) are most effective.</li><li>Guidelines recommend corticosteroids if MDF score &gt; 32 or MELD score &gt; 20.</li><li>MELD scores between 25 &amp; 39 provide maximum benefit.</li></ul>
                
        <details>
            <summary><strong>Corticosteroids</strong></summary>
            <div>
                <ul><li>Prednisolone associated w/ ↓ in 28-day mortality.</li><li>Survival benefit after 28 days not proven.</li><li>Heterogeneous use of corticosteroids in eligible patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Systematic Review Aim</strong></summary>
            <div>
                <ul><li>Identify optimal pharmacological treatment for severe AH to improve survival outcomes.</li><li>Primary outcome: mortality @ 28 days.</li><li>Secondary outcomes: mortality @ 90 days, adverse events, serious adverse events (infections, acute kidney injury, hepatorenal syndrome), withdrawal due to adverse events, liver transplantation rates.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Methods</strong></summary>
            <div>
                <ul><li>MEDLINE, EMBASE, CENTRAL searched to Feb 16, 2025.</li><li>RCTs of medical therapy for adults w/ severe AH included.</li><li>Primary outcome: mortality @ 28 days.</li></ul>
                
        <details>
            <summary><strong>Eligibility Criteria</strong></summary>
            <div>
                <ul><li>RCTs of adults (≥18 years) w/ severe AH (MDF ≥ 32 or MELD &gt;20) receiving drug treatment during hospitalization.</li><li>Any pharmacological therapy eligible.</li><li>Active-comparator or placebo-controlled trials eligible; English only.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Outcomes</strong></summary>
            <div>
                <ul><li>Primary: Overall mortality @ 28 days (30-day/1-month data substituted if unavailable).</li><li>Secondary: Mortality @ 90 days, adverse events, serious adverse events, withdrawal due to adverse events, incidence of hepatorenal syndrome, acute renal injury/infections, liver transplantation rates.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Data Analysis</strong></summary>
            <div>
                <ul><li>Risk ratio (RR) &amp; 95% confidence interval (CI) calculated for dichotomous outcomes.</li><li>Random-effects model used to pool data.</li><li>Heterogeneity assessed using chi-square test &amp; I2 statistic.</li></ul>
                
        <details>
            <summary><strong>I2 Interpretation</strong></summary>
            <div>
                <ul><li>&gt;75% = high heterogeneity; 50-75% = moderate; 25-50% = low; &lt;25% = minimal.</li><li>Sensitivity analysis conducted to explore heterogeneity.</li><li>Post hoc Bayesian network meta-analysis for mortality @ 28 &amp; 90 days.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Results</strong></summary>
            <div>
                <ul><li>52 RCTs (5,121 participants) included.</li><li>39 different comparisons made.</li><li>39 of 52 studies had unclear risk of bias for at least one item.</li></ul>
                
        <details>
            <summary><strong>Corticosteroids vs. Placebo</strong></summary>
            <div>
                <ul><li>10 studies (918 participants).</li><li>No statistically significant difference in mortality rates @ 28 days (RR 0.69, 95% CI 0.46-1.03, I2 = 61%, GRADE low certainty).</li><li>Sensitivity analysis (excluding outlier) showed statistically significant difference in mortality rates @ 28 days.</li></ul>
                
        <details>
            <summary><strong>Mortality Rates</strong></summary>
            <div>
                <ul><li>19% (84/449) of corticosteroids group died @ or before 28 days vs. 26% (116/441) of placebo (RR 0.62, 95% CI 0.41-0.95, I2 = 63%, GRADE low certainty).</li><li>No statistically significant difference in adverse events, serious adverse events, infections, acute kidney injury, or progression to hepatorenal syndrome.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Pentoxifylline vs. Corticosteroids</strong></summary>
            <div>
                <ul><li>7 studies (994 participants).</li><li>No statistically significant difference in mortality rates @ 28 days (RR 0.99, 95% CI 0.68-1.45, I2 = 60%, GRADE low certainty).</li><li>No statistically significant difference in mortality @ 90 days, adverse events, serious adverse events, withdrawal due to adverse events, infections, acute kidney injury, or progression to hepatorenal syndrome.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Pentoxifylline vs. Placebo</strong></summary>
            <div>
                <ul><li>3 studies (686 participants).</li><li>No statistically significant difference in mortality rates @ 28 days.</li><li>20% (67/332) of pentoxifylline group died @ or before 28 days vs. 23% (79/346) of placebo (RR 0.73, 95% CI 0.39-1.34, I2 = 70%, GRADE low certainty).</li></ul>
                
        <details>
            <summary><strong>Hepatorenal Syndrome</strong></summary>
            <div>
                <ul><li>Pentoxifylline patients significantly less likely to progress to hepatorenal syndrome.</li><li>8% (4/49) of pentoxifylline patients progressed vs. 35% (18/52) of placebo (RR 0.24, 95% CI 0.09-0.65, GRADE low certainty).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Metadoxine &amp; Corticosteroids vs. Corticosteroids</strong></summary>
            <div>
                <ul><li>1 study (70 participants).</li><li>Metadoxine + corticosteroids had significantly lower mortality rates @ 28 days than corticosteroids alone.</li><li>26% (9/35) vs. 54% (19/35) (RR 0.47, 95% CI 0.25-0.90, GRADE low certainty).</li></ul>
                
        <details>
            <summary><strong>90-Day Mortality</strong></summary>
            <div>
                <ul><li>Metadoxine + corticosteroids had significantly lower mortality rates @ 90 days.</li><li>31% (11/35) vs. 80% (28/35) (RR 0.39, 95% CI 0.23-0.66, GRADE moderate certainty).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Metadoxine &amp; Corticosteroids vs. Pentoxifylline</strong></summary>
            <div>
                <ul><li>1 study (68 participants).</li><li>Metadoxine + corticosteroids had significantly lower mortality rates @ 28 days than pentoxifylline.</li><li>26% (9/35) vs. 52% (17/33) (RR 0.50, 95% CI 0.26-0.96, GRADE low certainty).</li></ul>
                
        <details>
            <summary><strong>90-Day Mortality</strong></summary>
            <div>
                <ul><li>Metadoxine + corticosteroids had significantly lower mortality rates @ 90 days.</li><li>31% (11/35) vs. 67% (22/33) (RR 0.47, 95% CI 0.27-0.81, GRADE low certainty).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>G-CSF &amp; Pentoxifylline vs. Pentoxifylline</strong></summary>
            <div>
                <ul><li>3 studies (129 participants).</li><li>Combination therapy had significantly lower mortality rates @ 28 days.</li><li>17% (7/41) vs. 63% (27/43) (RR 0.27, 95% CI 0.13-0.54, I2 = 0%, GRADE low certainty).</li></ul>
                
        <details>
            <summary><strong>90-Day Mortality</strong></summary>
            <div>
                <ul><li>Combination therapy had significantly lower mortality rates @ 90 days.</li><li>17% (7/41) vs. 74% (32/43) (RR 0.32, 95% CI 0.16-0.63, I2 = 29%, GRADE moderate certainty).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Hepatorenal Syndrome</strong></summary>
            <div>
                <ul><li>Combination therapy had significantly lower rates of progression to hepatorenal syndrome.</li><li>4% (1/23) vs. 35% (8/23) (RR 0.13, 95% CI 0.02-0.92, GRADE low certainty).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Corticosteroids &amp; N-acetylcysteine vs. Corticosteroids</strong></summary>
            <div>
                <ul><li>1 study (174 participants).</li><li>Combination therapy had significantly lower mortality rate @ 28 days.</li><li>8% (7/85) vs. 24% (RR 0.35, 95% CI 0.16-0.78, GRADE low certainty).</li></ul>
                
        <details>
            <summary><strong>Infection and Hepatorenal Syndrome</strong></summary>
            <div>
                <ul><li>Combination therapy had significantly lower rates of infection (RR 0.45, 95% CI 0.27-0.75, GRADE moderate certainty) &amp; progression to hepatorenal syndrome (RR 0.48, 95% CI 0.24-0.94, GRADE low certainty).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Fecal Microbiota Transplant vs. Corticosteroids</strong></summary>
            <div>
                <ul><li>1 study (120 participants).</li><li>No statistically significant difference in mortality rates @ 28 days (RR 0.54, 95% CI 0.23-1.26, GRADE low certainty).</li><li>Fecal transplant group had significantly lower mortality rate @ 90 days (RR 0.58, 95% CI 0.34-0.98, GRADE moderate certainty).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Anakinra &amp; Zinc vs. Corticosteroids</strong></summary>
            <div>
                <ul><li>1 study (147 participants).</li><li>Combination therapy had significantly higher mortality rates @ 28 days.</li><li>19% (14/74) vs. 3% (2/73) (RR 6.91, 95% CI 1.63-29.32, GRADE low certainty).</li></ul>
                
        <details>
            <summary><strong>90-Day Mortality and Acute Kidney Injury</strong></summary>
            <div>
                <ul><li>Combination therapy had significantly higher mortality rates @ 90 days.</li><li>26% (19/74) vs. 10% (7/73) (RR 2.68, 95% CI 1.20-5.98, GRADE low certainty).</li><li>Combination therapy had significantly lower rates of acute kidney injury (RR 2.03, 95% CI 1.23-3.36, GRADE moderate certainty).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Bayesian Network Meta-analysis</strong></summary>
            <div>
                <ul><li>Treatment w/ corticosteroids, pentoxifylline, &amp; combination of NAC &amp; prednisolone significantly reduced risk of mortality @ 28 days compared to placebo.</li><li>Treatment w/ corticosteroids, combination therapy w/ G-CSF &amp; corticosteroids, &amp; combination therapy w/ metadoxine &amp; corticosteroids significantly reduced risk of mortality @ 90 days compared to placebo.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Discussion</strong></summary>
            <div>
                <ul><li>Corticosteroid use associated w/ 28-day mortality benefit compared to placebo.</li><li>Benefits seen w/ combination of N-acetylcysteine &amp; corticosteroids, pentoxifylline compared to placebo, G-CSF combined w/ pentoxifylline, &amp; metadoxine combined w/ corticosteroids.</li><li>No benefit found when pentoxifylline &amp; corticosteroids used in combination.</li></ul>
                
        <details>
            <summary><strong>Corticosteroids</strong></summary>
            <div>
                <ul><li>Aligns w/ previous studies showing short-term benefits in reducing 28-day mortality.</li><li>Benefit doesn&#x27;t extend to long-term mortality @ 90 days.</li><li>No differences observed between corticosteroids &amp; placebo for adverse events, serious adverse events, infections, acute kidney injury, or progression to hepatorenal syndrome.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Pentoxifylline</strong></summary>
            <div>
                <ul><li>No benefit observed w/ pentoxifylline vs. corticosteroids.</li><li>No differences in 28-day mortality when comparing pentoxifylline to placebo.</li><li>Pentoxifylline group less likely to progress to hepatorenal syndrome.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>G-CSF</strong></summary>
            <div>
                <ul><li>Combination of G-CSF &amp; pentoxifylline significantly reduced 28-day &amp; 90-day mortality compared to pentoxifylline alone.</li><li>Combination therapy showed lower rates of progression to hepatorenal syndrome.</li><li>Benefit of G-CSF in patients w/ AH should be viewed w/ caution.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Other Therapies</strong></summary>
            <div>
                <ul><li>Metadoxine combined w/ corticosteroids demonstrated reduction in mortality @ both 28 &amp; 90 days compared to pentoxifylline or corticosteroids alone.</li><li>Combination of corticosteroids &amp; NAC associated w/ reduced 28-day mortality, but w/o differences in 90-day mortality.</li><li>Fecal microbiota transplant vs. corticosteroids showed significantly lower mortality rate @ 90 days compared to corticosteroids.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Limitations</strong></summary>
            <div>
                <ul><li>Supportive care may have improved over time.</li><li>Lack of solid evidence-based treatments.</li><li>Heterogeneity among studies may introduce variability.</li><li>Treatment-related adverse events were generally poorly reported.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Conclusion</strong></summary>
            <div>
                <ul><li>Low certainty evidence supports efficacy of corticosteroids as first-line therapy for eligible patients w/ severe AH.</li><li>Benefits noted for combination of NAC &amp; corticosteroids vs. corticosteroids, G-CSF combined w/ pentoxifylline vs. pentoxifylline, &amp; metadoxine combined w/ corticosteroids vs. corticosteroids or pentoxifylline.</li><li>Further studies needed to confirm these benefits.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>What You Need to Know</strong></summary>
            <div>
                <ul><li>AH is a severe form of ALD, w/ short-term mortality up to 50% within 3 months.</li><li>To date, there is no consensus on the best therapeutic approach for severe AH.</li><li>A survival benefit at 28 days was observed for corticosteroids over placebo, for corticosteroids plus N-acetylcysteine over corticosteroids alone, for granulocyte colony-stimulating factor combined with pentoxifylline over pentoxifylline alone, and metadoxine combined with corticosteroids over corticosteroids alone or pentoxifylline.</li></ul>
                
        <details>
            <summary><strong>Implications for Patient Care</strong></summary>
            <div>
                <ul><li>Low certainty evidence supports efficacy of corticosteroids as first line therapy for eligible patients w/ severe AH.</li><li>The certainty of the evidence supporting other therapies ranges from low to moderate, indicating the need for further studies to confirm these benefits.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
